| Heading: |
Finasteride |
| Question ID: |
1750573 |
| UIN: |
20625 |
| House: |
Commons |
| Date tabled: |
2024-12-17 |
| Asking Member ID: |
4357 |
| Asking Member display name: |
Kirsty Blackman
|
| Asking Member handle: |
KirstySNP
|
| Asking Member Twitter reference: |
@KirstySNP
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential impact of the sales Finasteride medications through telehealth companies on an increase in the level of cases of Post-Finasteride Syndrome in the |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2024-12-31 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Medicines and Healthcare products Regulatory Agency’s (MHRA) role is to continually monitor the safety of medicines during their use. We have robust, safety monitoring and surveillance systems in place for all healthcare products, including finasterid... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |